**Author details**

Ludovica Parisi1,2, Carlo Galli1,2,4\*, Lisa Elviri3 , Annalisa Bianchera3 , Paola Lagonegro4 , Simone Lumetti1,2, Edoardo Manfredi1,2 and Guido Maria Macaluso1,2,4

\*Address all correspondence to: carlo.galli@unipr.it

1 Department of Biomedical Biotechnological and Translational Sciences, University of Parma, Parma, Italy


### **References**


[5] Giannoudis, P.V., T.A. Einhorn, and D. Marsh, Fracture healing: the diamond con‐ cept. Injury, 2007. 38 Suppl 4: p. S3–S6.

**Acknowledgements**

346 Advanced Techniques in Bone Regeneration

**Conflict of interest**

**Author details**

Parma, Italy

**References**

3(1): p. 1–5.

Med, 2011. 9: p. 66.

The study was supported by a 2013 grant by the American Academy of Implant Dentistry Foundation. We thank Dr. Bill Jackson and Dr. Lisa Thurston (Base Pair Biotechnologies, Pearland, TX, USA) fortheir precious advice. We also thank Dr. Gallia Graiani and Dr. Andrea Toffoli (Dentistry Center, University of Parma), Dr. Benedetta Ghezzi, Dr. Anna Lidia Perruccio, Dr. Maria Siciliano, Dr. Alessandra Zecca (Department of Biomedical Biotechno‐

, Annalisa Bianchera3

1 Department of Biomedical Biotechnological and Translational Sciences, University of Parma,

[1] Mason, C. and P. Dunnill, A brief definition ofregenerative medicine. Regen Med, 2008.

[2] Langer, R. and J.P. Vacanti, Tissue engineering. Science, 1993. 260(5110): p. 920–926.

[3] Dimitriou, R., et al., Bone regeneration: current concepts and future directions. BMC

[4] Oryan, A., et al., Bone regenerative medicine: classic options, novel strategies, and

, Paola Lagonegro4

,

logical and Translational Sciences, University of Parma) for their assistance.

Simone Lumetti1,2, Edoardo Manfredi1,2 and Guido Maria Macaluso1,2,4

The authors have no conflict of interest to disclose.

Ludovica Parisi1,2, Carlo Galli1,2,4\*, Lisa Elviri3

\*Address all correspondence to: carlo.galli@unipr.it

2 Dentistry Center, University of Parma, Parma, Italy

4 IMEM-CNR, University of Parma, Parma, Italy

3 Department of Pharmacy, University of Parma, Parma, Italy

future directions. J Orthop Surg Res, 2014. 9(1): p. 18.


[20] Ohgushi, H., et al., Tissue engineered ceramic artificial joint – ex vivo osteogenic differentiation of patient mesenchymal cells on total ankle joints for treatment of

[21] Kim, S.J., et al., A multi-center, randomized, clinical study to compare the effect and safety of autologous cultured osteoblast (Ossron) injection to treat fractures. BMC

[22] Langer, R. andD.A. Tirrell, Designing materials for biology and medicine. Nature, 2004.

[23] Dhandayuthapani, S., et al., Bromelain-induced apoptosis in GI-101A breast cancer

[24] Kikuchi, M., Hydroxyapatite/collagen bone-like nanocomposite. Biol Pharm Bull, 2013.

[25] Lee, S.S., et al., Bone regeneration with low dose BMP-2 amplified by biomimetic supramolecular nanofibers within collagen scaffolds. Biomaterials, 2013. 34(2): p. 452–

[26] Pastorino, L., et al., Oriented collagen nanocoatings for tissue engineering. Colloids

[27] Nishiyama, Y., P. Langan, and H. Chanzy, Crystal structure and hydrogen-bonding system in cellulose Ibeta from synchrotron X-ray and neutron fiber diffraction. J Am

[28] Agnihotri, S.A., N.N. Mallikarjuna, and T.M. Aminabhavi, Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release, 2004.

[29] Aravamudhan, A., et al., Cellulose and collagen derived micro-nano structured scaffolds for bone tissue engineering. J Biomed Nanotechnol, 2013. 9(4): p. 719–731.

[30] Perez, R.A., et al., Utilizing core-shell fibrous collagen-alginate hydrogel cell delivery system for bone tissue engineering. Tissue Eng Part A, 2014. 20(1–2): p. 103–114. [31] Mistura, D.V., et al., Development, characterization, and cellular adhesion of poly(Llactic acid)/poly(caprolactone triol) membranes for potential application in bone tissue

[32] Perez, R.A. and M.P. Ginebra, Injectable collagen/alpha-tricalcium phosphate cement: collagen-mineral phase interactions and cell response. J Mater Sci Mater Med, 2013.

[33] Williams, D.F., On the mechanisms of biocompatibility. Biomaterials, 2008. 29(20): p.

osteoarthritis. Biomaterials, 2005. 26(22): p. 4654–4661.

Musculoskelet Disord, 2009. 10: p. 20.

cells. J Med Food, 2012. 15(4): p. 344–349.

Surf B Biointerfaces, 2014. 114: p. 372–378.

Chem Soc, 2002. 124(31): p. 9074–9082.

regeneration. Artif Organs, 2013. 37(11): p. 978–984.

428(6982): p. 487–492.

348 Advanced Techniques in Bone Regeneration

36(11): p. 1666–1669.

100(1): p. 5–28.

24(2): p. 381–393.

2941–2953.

459.


[64] Eyetech Study, G., Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina, 2002. 22(2): p. 143–152.

[48] Dee, K.C., T.T. Anderson, and R. Bizios, Osteoblast population migration characteris‐ tics on substrates modified with immobilized adhesive peptides. Biomaterials, 1999.

[49] Zreiqat, H., et al., Differentiation of human bone-derived cells grown on GRGDSPpeptide bound titanium surfaces. J Biomed Mater Res A, 2003. 64(1): p. 105–113.

[50] Ferris, D.M., et al., RGD-coated titanium implants stimulate increased bone forma‐

[51] Elmengaard, B., J.E. Bechtold, and K. Soballe, In vivo effects of RGD-coated titanium implants inserted in two bone-gap models. J Biomed Mater Res A, 2005. 75(2): p. 249–

[52] Rammelt, S., et al., Coating of titanium implants with collagen, RGD peptide and

[53] Hennessy, K.M., et al., The effect of RGD peptides on osseointegration of hydroxya‐

[54] Geissler, U., et al., Collagen type I-coating of Ti6Al4V promotes adhesion of osteo‐

[55] Roehlecke, C., et al., Synergistic effect of titanium alloy and collagen type I on cell adhesion, proliferation and differentiation of osteoblast-like cells. Cells Tissues Organs,

[56] Huang, L., et al., The effect of hyaluronan on osteoblast proliferation and differentia‐ tion in rat calvarial-derived cell cultures. J Biomed Mater Res A, 2003. 66(4): p. 880–884.

[57] Takada, T., et al., Sulfated polysaccharides enhance the biological activities of bone

[58] Song, K.M., S. Lee, and C. Ban, Aptamers and their biological applications. Sensors

[59] Ellington, A.D. and J.W. Szostak, In vitro selection of RNA molecules that bind specific

[60] Mascini, M., I. Palchetti, and S. Tombelli, Nucleic acid and peptide aptamers: funda‐ mentals and bioanalytical aspects. Angew Chem Int Ed Engl, 2012. 51(6): p. 1316–1332.

[61] Ku, T.H., et al., Nucleic acid aptamers: an emerging tool for biotechnology and

[62] Sun, H. and Y. Zu, A highlight of recent advances in aptamer technology and its

[63] Geiger, A., et al., RNA aptamers that bind L-arginine with sub-micromolar dissocia‐ tion constants and high enantioselectivity. Nucleic Acids Res, 1996. 24(6): p. 1029–1036.

morphogenetic proteins. J Biol Chem, 2003. 278(44): p. 43229–43235.

biomedical sensing. Sensors (Basel), 2015. 15(7): p. 16281–16313.

application. Molecules, 2015. 20(7): p. 11959–11980.

tion in vivo. Biomaterials, 1999. 20(23–24): p. 2323–2331.

chondroitin sulfate. Biomaterials, 2006. 27(32): p. 5561–5571.

patite biomaterials. Biomaterials, 2008. 29(21): p. 3075–3083.

blasts. J Biomed Mater Res, 2000. 51(4): p. 752–760.

2001. 168(3): p. 178–187.

(Basel), 2012. 12(1): p. 612–631.

ligands. Nature, 1990. 346(6287): p. 818–822.

20(3): p. 221–227.

350 Advanced Techniques in Bone Regeneration

255.


[96] Inc, E., Phase 3 study presented at world ophthalmology congress evaluates investi‐ gational use of macugen in patients with diabetic macular edema. 2010.

[80] Joeng, C.B., et al., ssDNA aptamers that recognize diclofenac and 2-anilinophenylace‐

[81] Mendonsa, S.D. and M.T. Bowser, In vitro selection of high-affinity DNA ligands for human IgE using capillary electrophoresis. Anal Chem, 2004. 76(18): p. 5387–5392.

[82] Mendonsa, S.D. and M.T. Bowser, In vitro selection of aptamers with affinity for neuropeptide Y using capillary electrophoresis. J Am Chem Soc, 2005. 127(26): p. 9382–

[83] Kunii, T., et al., Selection of DNA aptamers recognizing small cell lung cancer using

[84] Van Simaeys, D., et al., Study of the molecularrecognition of aptamers selected through

[85] Daniels, D.A., et al., A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution ofligands by exponential enrichment. Proc Natl Acad Sci U S A, 2003. 100(26):

[86] Gold, L., et al., Diversity of oligonucleotide functions. Annu Rev Biochem, 1995. 64: p.

[87] Green, L.S., et al., Inhibitory DNA ligands to platelet-derived growth factor B-chain.

[88] Zhou, J., et al., Structural prediction and binding analysis of hybridized aptamers. J Mol

[89] Shigdar, S., et al., RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett,

[90] Qiao, L., et al., A new application of aptamer: one-step purification and immobiliza‐ tion of enzyme from cell lysates for biocatalysis. J Biotechnol, 2015. 203: p. 68–76.

[91] Saberian-Borujeni, M., et al., Nanoscaled aptasensors for multi-analyte sensing.

[92] Chen, A. and S. Yang, Replacing antibodies with aptamers in lateral flow immunoas‐

[93] Wu, J., et al., Recent trends in SELEX technique and its application to food safety

[94] Hayat, A. and J.L. Marty, Aptamer based electrochemical sensors for emerging environmental pollutants. Front Chem, 2014. 2 41 doi: 10.3389/fchem.2014.00041.

[95] Lee, J.H., F. Jucker, and A. Pardi, Imino proton exchange rates imply an induced-fit binding mechanism for the VEGF165-targeting aptamer, Macugen. FEBS Lett, 2008.

tic acid. Bioorg Med Chem, 2009. 17(15): p. 5380–5387.

living cell-SELEX. Analyst, 2011. 136(7): p. 1310–1312.

Biochemistry, 1996. 35(45): p. 14413–14424.

Recognit, 2011. 24(1): p. 119–126.

Bioimpacts, 2014. 4(4): p. 205–215.

say. Biosens Bioelectron, 2015. 71: p. 230–242.

monitoring. Mikrochim Acta, 2014. 181(5–6): p. 479–491.

2013. 330(1): p. 84–95.

582(13): p. 1835–1839.

ovarian cancer cell-SELEX. PLoS One, 2010. 5(11): p. e13770.

9383.

352 Advanced Techniques in Bone Regeneration

p. 15416–15421.

763–797.


[124] Stecker, J.R., et al., Dynamics and visualization of MCF7 adenocarcinoma cell death by aptamer-C1q-mediated membrane attack. Nucleic Acid Ther, 2012. 22(4): p. 275–282.

[109] Bates, P.J., et al., Antiproliferative activity of G-rich oligonucleotides correlates with

[110] Bruno, J.G., Predicting the uncertain future of aptamer-based diagnostics and thera‐

[111] Duclair, S., et al., High-affinity RNA aptamers against the HIV-1 protease inhibit both in vitro protease activity and late events of viralreplication. Mol Ther Nucl Acids, 2015.

[112] Cheng, C., et al., Potent inhibition of human influenza H5N1 virus by oligonucleoti‐ des derived by SELEX. Biochem Biophys Res Commun, 2008. 366(3): p. 670–674.

[113] Binning, J.M., et al., Development of RNA aptamers targeting Ebola virus VP35.

[114] Shum, K.T., J. Zhou, and J.J. Rossi, Aptamer-based therapeutics: new approaches to combat human viral diseases. Pharmaceuticals (Basel), 2013. 6(12): p. 1507–1542.

[115] Wandtke, T., J. Wozniak, and P. Kopinski, Aptamers in diagnostics and treatment of

[116] Gopinath, S.C. and P.K. Kumar, Aptamers that bind to the hemagglutinin of the recent pandemic influenza virus H1N1 and efficiently inhibit agglutination. Acta Biomater,

[117] Kwon, H.M., et al., An RNA aptamer that specifically binds to the glycosylated hemagglutinin of avian influenza virus and suppresses viral infection in cells. PLoS

[118] Musafia, B., R. Oren-Banaroya, and S. Noiman, Designing anti-influenza aptamers: novel quantitative structure activity relationship approach gives insights into aptam‐

[119] Shiratori, I., et al., Selection of DNA aptamers that bind to influenza A viruses with high affinity and broad subtype specificity. Biochem Biophys Res Commun, 2014.

[120] Suenaga, E. and P.K. Kumar, An aptamer that binds efficiently to the hemagglutinins of highly pathogenic avian influenza viruses (H5N1 and H7N7) and inhibits hemag‐

[121] Bruno, J.G., et al., Development of DNA aptamers for cytochemical detection of

[122] Bruno, J.G., et al., A novel screening method for competitive FRET-aptamers applied

[123] Schlesinger, S.R., et al., Metallo-β-lactamases and aptamer-based inhibition. Pharma‐

glutinin-glycan interactions. Acta Biomater, 2014. 10(3): p. 1314–1323.

acetylcholine. In Vitro Cell Dev Biol Anim, 2008. 44(3–4): p. 63–72.

to *E. coli* assay development. J Fluoresc, 2010. 20(6): p. 1211–1223.

ceuticals 2011, 4, 419–428 doi: 10.3390/ph4020419

protein binding. J Biol Chem, 1999. 274(37): p. 26369–26377.

peutics. Molecules, 2015. 20(4): p. 6866–6887.

Biochemistry, 2013. 52(47): p. 8406–8419.

viral infections. Viruses, 2015. 7(2): p. 751–780.

er-virus interaction. PLoS One, 2014. 9(5): p. e97696.

2013. 9(11): p. 8932–8941.

One, 2014. 9(5): p. e97574.

443(1): p. 37–41.

4: p. e228.

354 Advanced Techniques in Bone Regeneration

